Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

Abstract

Our study demonstrated that the observed immune signature in the peripheral blood of melanoma patients prior to treatment could identify responders as well as non-responders that benefit from ICI immunotherapies.